Use of Heparin in Women With Early and Late Miscarriages With and Without Thrombophilia

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 6, 2009, Pages 636-644

  Monien, Silke ^a   Kadecki, Oliver ^a   Baumgarten, Susanne ^b   Salama, Abdulgabar ^a   Dörner, Thomas ^a   Kiesewetter, Holger ^a  

^a NeuroCure Clinical Research Center   (Germany)

^b Hormone and Fertility Centre   (Germany)

Author keywords

abortions; fetal loss; heparin; thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; INFLAMMATION; LIVE BIRTH; PREGNANCY; PREGNANCY OUTCOME; RECURRENT ABORTION; THROMBOPHILIA;

ABORTION, HABITUAL; ADULT; AGE FACTORS; ASPIRIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DALTEPARIN; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFLAMMATION; LIVE BIRTH; PREGNANCY; PREGNANCY OUTCOME; THROMBOPHILIA; YOUNG ADULT;

EID: 75549084111     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609335501     Document Type: Article

References (58)

1. Rai R., Regan L., Hadley E., Dave M., Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol. 1996; 92: 489-490.
2. Sanson BJ, Friederich PW, Simioni P., Zanardi S., Hilsman MV, Girolami A. The risk of abortion and still-birth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 1996; 75(3):387-388.
3. Grandone E., Margaglione M., Colaizzo D., et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 1997; 77(5): 822-824.
4. Brenner B., Sarig G., Weiner Z., Younis J., Blumenfeld Z., Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost. 1999; 82(1):6-9.
5. Meinardi JR, Middeldorp S., de Kam PJ, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med. 1999; 130(9):736-739.
6. Foka ZJ, Lambropoulos AF, Karas GB, Karavida A., Agorastos T. Factor V. Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod. 2000; 1(5):458-462.
7. Younis JS, Brenner B., Ohel G., Tal J., Lanir N., Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol. 2000; 43(1):31-35.
8. Raziel A., Kornberg Y., Friedler S., Schachter M., Sela BA, Ron-El R. Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. Am J Reprod Immunol. 2001; 45(2):65-71.
9. Sarig G., Younis JS, Hoffman R., Lanir N., Blumenfeld Z., Brenner B. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril. 2002; 77(2):342-347.
10. Rey E., Kahn SR, David M., Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003; 361(9361):901-908.
11. Brenner B., Kupferminc M. Inherited thrombophilia and poor pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2003; 17(3):427-439.
12. Kujovich JL Thrombophilia and pregnancy complications. Am J Obstet Gynecol. 2004; 191(2):412-424.
13. Braulke I., Pruggmayer M., Melloh P., Hinney B., Kostering H., Gunther E. Factor XII (Hageman) deficiency in woman with habitual abortion: new subpopulation of recurrent aborters? Fertil Steril. 1993; 59(1): 98-101.
14. Yamada H., Kato EH, Ebina Y., et al. Factor XII deficiency in women with recurrent miscarriage. Gynecol Obstet Invest. 2000; 49(2):80-83.
15. Glueck CJ, Kupferminc MJ, Fontaine RN Genetic hypo-fibrinolysis in complicated pregnancies. Obstet Gynecol. 2001; 97(1):44-48.
16. Gris JC, Quere I., Dechaud H., et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood. 2002; 99(7):2606-2608.
17. Dilley A., Benito C., Hooper WC, et al. Mutations in the factor V, prothombin and MTHFR genes are not risk factors for recurrent fetal loss. J Matern Fetal Neonatal Med. 2002; 11(3):176-182.
18. Buchholz T., Lohse P., Rogenhofer N., Kosian E., Pihusch R., Thaler CJ Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages. Hum Reprod. 2003; 18(11):2473-2477.
19. Stirrat GM. Recurrent miscarriage 1: definition and epidemiology. Lancet. 1990; 336(8716):673-675.
20. Rai R., Clifford K., Cohen H., Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995; 10(12):3301.
21. Rai R., Backos M., Baxter N., Chilcott I., Regan L. Recurrent miscarriage-an aspirin a day? Hum Reprod. 2000; 15(10):2220-2223.
22. Rai R., Backos M., Elgaddal S., Shlebak A., Regan L. Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies. Hum Reprod. 2002; 17(2):442-445.
23. Carp H., Dolitzky M., Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost. 2003; 1(3):433-438.
24. Younis JS, Ohel G., Brenner B., Haddad S., Lanir N., Ben-Ami M. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG. 2000; 107(3):415-419.
25. Brenner B., Hoffman R., Blumenfeld Z., Weiner Z., Younis JS Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000; 83(5):693-697.
26. Sarto A., Rocha M., Geller M., et al. Treatment with enoxaparin adapted to the fertility programs in women with recurrent abortion and thrombophilia. Medicina. 2001; 61(4):406-412.
27. Kupferminc MJ, Fait G., Many A., et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001; 20(1):35-44.
28. Brenner B. Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss. Blood. 2002; 100(11):2765.
29. Tzafettas J., Petropoulos P., Psarra A., et al. Early antiplatelet and antithrombotic therapy in patients with a history of recurrent miscarriages of known and unknown aetiology. Eur J Obstet Gynecol Reprod Biol. 2005; 120(1):22-26.
30. Grandone E., Brancaccio V., Colaizzo D., et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril. 2002; 78(2):371-375.
31. Brenner B., Hoffman R., Carp H., Dulitzky M., Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost. 2005; 3(2):227-9.
32. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996; 174(5):1584-1589.
33. Rai R., Cohen H., Dave M., Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997; 314(7076):253-257.
34. Backos M., Rai R., Baxter N., Chilcott IT, Cohen H., Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol. 1999; 106(2):102-107.
35. Empson M., Lassere M., Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obst Gynecol. 2002; 99(1):135-144.
36. Triolo G., Ferrante A., Ciccia F., et al. Randomized Study of Subcutaneous Low Molecular Weight Heparin Plus Aspirin Versus Intravenous Immunoglobulin in the Treatment of Recurrent Fetal Loss Associated With Antiphospholipid Antibodies. Arthritis Rheum. 2003; 48(3):728-731.
37. Girardi G., Redecha P., Salmon J. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10(11): 1222-1226.
38. Wang L., Brown JR, Varki A., Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest. 2002; 110(1):127-136.
39. Out HJ, Kooijman CD, Bruinse JW, Derksen RHWM. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol. 1991; 41(3): 179-186.
40. Dizon-Townson DS, Meline L., Nelson LM, Varner M., Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol. 1997; 177(2):402-405.
41. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod. 2000; 15(8):1830-1833.
42. Many A., Schreiber L., Rosner S., Lessing JB, Eldor A., Kupferminc MJ. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol. 2001; 98(6):1041-1044.
43. Sebire NJ, Fox H., Backos M., Rai R., Paterson C., Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod. 2002; 17(4):1067-1071.
44. Hoppe B., Heymann GA, Koscielny J., Hellstern P., Kiesewetter H., Salama A. Screening for multiple hereditary hypercoagulability factors using the amplification refractory mutation system. Thromb Res. 2003;111(1-2):115-120.
45. Miyashita Y., Waguri M., Nakanishi I., Suehara N., Fujita T. Successful pregnancy with low molecular weight heparin in two women with recurrent miscarriage of unknown etiology. Am J Reprod Immunol. 2003; 49(2): 90-92.
46. Wegmann TG, Lin H., Guilbert L., Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol Today. 1993; 14(7):353-356.
47. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996; 17(3):138-146.
48. Raghupathy R. Pregnancy: success and failure within the Th1/Th2/Th3 paradigm. Semin Immunol. 2001; 13(4):219. 49.
49. Costeas PA, Koumouli A., Giantsiou-Kyriakou A., Papaloizou A., Koumas L. Th2/Th3 cytokine genotypes are associated with pregnancy loss. Human Immunol. 2004; 65(2):135-141.
50. Matsumori A., Koh O., Masaharu O., Tadashi M., Yukihito S., Shigetake S. Immediate increase in circulating hepatocyte growth factor/scatter factor by haparin. J Mol Cell Cardiol. 1998; 30(10):2145-2149.
51. Okada M., Sugita K., Inukai T., et al. Hepatocyte growth factor protects small airway epithelial cells from apoptosis induced by tumor necrosis factor-alpha or oxidative stress. Pediatr Res. 2004; 56(3): 336-344.
52. Clark DA, Ding JW, Chaouat G., Coulam CB, August C., Levy GA The emerging role of immunoregulation of fibrinogen-related procoagulant Fgl2 in the success or spontaneous abortion of early pregnancy in mice and humans. Am J Reprod Immunol. 1999; 42(1):37-43.
53. Erlebacher A., Zhang D., Parlow AF, Glimcher LH Ovarian insufficiency and early pregnancy loss induced by activation of the innate immune system. J Clin Invest. 2004; 114(1):39-48.
54. Arck PC, Rose M., Hertwig K., Hagen E., Hildebrandt M., Klapp BF Stress and immune mediators in miscarriage. Hum Reprod. 2001; 16(7):1505-1511.
55. Tichenor JR, Bledsoe LB, Opsahl MS, Cunningham DS Activation of complement in humans with a first-trimester pregnancy loss. Gynecol Obstet Invest. 1995; 39(2): 79-82.
56. Xu C., Mao D., Holers VM, Palanca B., Cheng AM, Molina H. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science. 2000; 287(5452):498-501.
57. Salmon JE, Girardi G., Holers VM Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002; 61(suppl 2):46-60.
58. Berman J., Girardi G., Salmon JE TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005; 174(1): 485-490.